![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Riccardo Scotto, Antonio Riccardo Buonomo, Stefania De Pascalis, Mariagiovanna Nerilli, Biagio Pinchera, Laura Staiano, Simona Mercinelli, Letizia Cattaneo, Maria Stanzione, Gianfranca Stornaiuolo, Salvatore Martini, Vincenzo Messina, Carmine Coppola, Nicola Coppola & Ivan Gentile. (2021) Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results. Expert Review of Gastroenterology & Hepatology 15:9, pages 1057-1063.
Read now
Read now
Vincent Soriano, Pablo Labarga, Carmen de Mendoza, José V Fernández-Montero, Isabella Esposito, Laura Benítez-Gutiérrez, José M Peña & Pablo Barreiro. (2016) New hepatitis C therapies for special patient populations. Expert Opinion on Pharmacotherapy 17:2, pages 217-229.
Read now
Read now
Michael A Smith & Alice Lim. (2015) Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Design, Development and Therapy 9, pages 6083-6094.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Riccardo Scotto & Guglielmo Borgia. (2015) Asunaprevir for hepatitis C: a safety evaluation. Expert Opinion on Drug Safety 14:10, pages 1631-1646.
Read now
Read now
Emily L Heil, Lauren M Hynicka, Shyam Kottilil & Lydia Tang. (2015) What does the pharmacological future of treating chronic hepatitis C look like?. Expert Review of Clinical Pharmacology 8:5, pages 605-622.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Alberto Enrico Maraolo & Guglielmo Borgia. (2015) Beclabuvir for the treatment of hepatitis C. Expert Opinion on Investigational Drugs 24:8, pages 1111-1121.
Read now
Read now
Ashley Arezou Minaei & Kris V Kowdley. (2015) ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opinion on Pharmacotherapy 16:6, pages 929-937.
Read now
Read now
Vincent Soriano, Pablo Labarga, Pablo Barreiro, José V Fernandez-Montero, Carmen de Mendoza, Isabella Esposito, Laura Benítez-Gutiérrez & José M Peña. (2015) Drug interactions with new hepatitis C oral drugs. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 333-341.
Read now
Read now
Articles from other publishers (8)
Nitesh K. Gupta, Srinivasan Jayakumar, Wen-Chieh Huang, Pieter Leyssen, Johan Neyts, Sergey O. Bachurin, Jih Ru Hwu & Shwu-Chen Tsay. (2022) Bis(Benzofuran–1,3-N,N-heterocycle)s as Symmetric and Synthetic Drug Leads against Yellow Fever Virus. International Journal of Molecular Sciences 23:20, pages 12675.
Crossref
Crossref
Vicky Mody, Joanna Ho, Savannah Wills, Ahmed Mawri, Latasha Lawson, Maximilian C. C. J. C. Ebert, Guillaume M. Fortin, Srujana Rayalam & Shashidharamurthy Taval. (2021) Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Communications Biology 4:1.
Crossref
Crossref
Riccardo Scotto, Antonio Riccardo Buonomo, Nicola Schiano Moriello, Alberto Enrico Maraolo, Emanuela Zappulo, Biagio Pinchera, Ivan Gentile & Guglielmo Borgia. (2019) Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. Reviews on Recent Clinical Trials 14:3, pages 173-182.
Crossref
Crossref
Bradley R Jones, Anita Y M Howe, P Richard Harrigan & Jeffrey B Joy. (2018) The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus. Virus Evolution 4:1.
Crossref
Crossref
John T. Randolph, Charles A. Flentge, Pamela Donner, Todd W. Rockway, Sachin V. Patel, Lissa Nelson, Douglas K. Hutchinson, Rubina Mondal, Neeta Mistry, Thomas Reisch, Tatyana Dekhtyar, Preethi Krishnan, Tami Pilot-Matias, Deanne F. Stolarik, David W.A. Beno, Rolf Wagner, Clarence Maring & Warren M. Kati. (2016) Discovery of fluorobenzimidazole HCV NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters 26:22, pages 5462-5467.
Crossref
Crossref
Emma Hathorn & Ahmed M Elsharkawy. (2016) Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterology 3:1, pages e000112.
Crossref
Crossref
Eric Lawitz, Greg Sullivan, Maribel Rodriguez-Torres, Michael Bennett, Fred Poordad, Mudra Kapoor, Prajakta Badri, Andrew Campbell, Lino RodriguesJr.Jr., Yiran Hu, Tami Pilot-Matias & Regis A. Vilchez. (2015) Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. Journal of Infection 70:2, pages 197-205.
Crossref
Crossref
Hui-Chun Li. (2015) Hepatitis C virus: Virology, diagnosis and treatment. World Journal of Hepatology 7:10, pages 1377.
Crossref
Crossref